In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI-01, while building the next generation of genomic medicines to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback